Polyphenol (-)-Epigallocatechin Gallate during Ischemia Limits Infarct Size Via Mitochondrial K_{ATP} Channel Activation in Isolated Rat Hearts

Polyphenol (-)-epigallocatechin gallate (EGCG), the most abundant catechin of green tea, appears to attenuate myocardial ischemia/reperfusion injury. We investigated the involvement of ATP-sensitive potassium (K_{ATP}) channels in EGCG-induced cardioprotection. Isolated rat hearts were subjected to 30 min of regional ischemia and 2 hr of reperfusion. EGCG was perfused for 40 min, from 10 min before to the end of index ischemia. A nonselective K_{ATP} channel blocker glibenclamide (GLI) and a selective mitochondrial K_{ATP} (mK_{ATP}) channel blocker 5-hydroxydecanoate (HD) were perfused in EGCG-treated hearts. There were no differences in coronary flow and cardiodynamics including heart rate, left ventricular developed pressure, rate-pressure product, +dP/dt_{max}, and -dP/dt_{min} throughout the experiments among groups. EGCG-treatment significantly reduced myocardial infarction (14.5 ± 2.5% in EGCG 1 μM and 4.0 ± 1.7% in EGCG 10 μM, P < 0.001 vs. control 27.2 ± 1.4%). This anti-infarct effect was totally abrogated by 10 μM GLI (24.6 ± 1.5%, P < 0.001 vs. EGCG). Similarly, 100 μM HD also aborted the anti-infarct effect of EGCG (24.1 ± 1.2%, P < 0.001 vs. EGCG). These data support a role for the K_{ATP} channels in EGCG-induced cardioprotection. The mK_{ATP} channels play a crucial role in the cardioprotection by EGCG.

Key Words : Epigallocatechin Gallate; K_{ATP} Channels; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury

INTRODUCTION

Green tea, a world wide consuming beverage, is known to have the beneficial effects on the cardiovascular system. In fact, the intake of green tea in human is proposed to be associated with a lower incidence of coronary artery disease (1) and myocardial infarction (2). In addition, there is evidence that the consumption of green tea reduces mortality due to cardiovascular disease in a large population prospective study (3). Furthermore, polyphenol (-)-epigallocatechin gallate (EGCG), the most prominent catechin of green tea, appears to attenuate myocardial ischemia/reperfusion (I/R) injury in animal models (4, 5). However, there is scanty information available about the molecular mechanisms involved in the EGCG-induced cardioprotection so far.

Meanwhile, the intracellular calcium ([Ca^{2+}]i) overload has been implicated as a primary event in cell injury and necrosis in myocardial I/R injury (6). Opening of adenosine triphosphate-sensitive potassium (K_{ATP}) channels prevents the [Ca^{2+}]i overload induced by myocardial I/R injury (7). Recent studies have suggested that mitochondrial K_{ATP} (mK_{ATP}) channels are responsible for the marked cardioprotective effect of myocardial ischemic preconditioning and pre-ischemic drug treatment to reduce infarct size (8, 9). Furthermore, there is accumulating evidence that the cardioprotective effects of K_{ATP} channel openers are associated with mK_{ATP} activation (10).

In this regard, it’s reasonable to hypothesize that the activation of mK_{ATP} channels may participate in the cardioprotective effect by EGCG. Therefore, the purpose of this study was to determine the involvement of mK_{ATP} channels in EGCG-induced pharmacological preconditioning in isolated rat hearts.

MATERIALS AND METHODS

The experimental procedures and protocols used in this study were reviewed and approved by our institutional animal care and use committee of Keimyung University Dongsan Medical Center.
Chemicals and antibodies

Pentobarbital sodium (Entobar®) was purchased from Hanlim Pharmacy (Yongin, Korea). EGCG and a selective blocker of mKATP channels (5-hydroxydecanoate, HD) were purchased from Sigma-Aldrich Chemical (St. Louis, MO, USA). A nonselective KATP channel blocker glibenclamide (GLI) was obtained from Tocris Bioscience (Ellisville, MO, USA). 2,3,5-Triphenyltetrazolium chloride (TTC) was also obtained from Sigma-Aldrich Chemical. Fluorescent polymer microspheres were purchased from Duke Scientific Corp. (Palo Alto, CA, USA). Other chemicals were obtained from Sigma-Aldrich Chemical.

Langendorff isolated heart perfusion preparation

Male Wistar rats, weighing 280-330 g obtained from Korea Takonic (Seongnam, Korea), were used throughout the experiments. They received 100 mg/kg of pentobarbital sodium and 300 IU of heparin intraperitoneally. Hearts were isolated and perfused with modified Krebs-Henseleit solution containing (in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4, and 10 glucose, as described previously (11). In order to induce regional ischemia, the proximal portion of left coronary artery (LCA) was first localized between the left atrial appendage and the right ventricular outflow tract. This was then followed by the passage of a 6-0 polypropylene suture around the major trunk of the LCA or its prominent branches. The ends of the thread were passed through a small piece of PE50 tube to form a snare. All hearts were then allowed to stabilize for at least 30 min. Ischemia was induced by pulling the snare and then fixing it by clamping the tubing with a small hemostat and was confirmed by regional cyanosis, a substantial decrease in left ventricular developed pressure (LVDP), or a fall in coronary flow. Reperfusion was initiated by releasing the snare. Hearts experiencing ventricular fibrillation (VF) usually revert spontaneously to sinus rhythm. VF lasting more than 45 sec was treated with finger flick cardioversion until a perfusing rhythm was obtained. No pharmacological agents were used for defibrillation.

Assessment of cardiac function

The functional recovery by EGCG was compared with control hearts. To do this, an air-bubble free, Krebs-Henseleit buffer-filled elastic balloon made of polyethylene plastic connected to a pressure transducer with tubing was inserted into the left ventricle (LV) through the left atrial appendage. The balloon was coupled to a graded threaded micro-syringe and balloon volume was adjusted to give a left ventricular enddiastolic pressure (LVEDP) of 5-10 mmHg at the beginning of the experiment. LVDP was calculated as the difference between the left ventricular systolic pressure (LVSP) and LVEDP.

 Coronary flow was measured by a timed collection of the perfusate dripping from the right heart into a graduated cylinder. Cardiodynamic data, including heart rate, LVSP, LVEDP, and the maximum and minimum of first derivative of left ventricular pressure (+dP/dtmax and -dP/dtmin) were continuously recorded with the MP150 pressure transducer (BioPac Systems, Santa Barbara, CA, USA), and analyzed using analysis software (Acqknowledge, version 3.9.0.). The rate-pressure product (RPP) was calculated as LVDP × heart rate (12).

Experimental protocol

All hearts were subjected to 30 min of regional ischemia and 2 hr of reperfusion and each group consisted of at least 7 hearts. Isolated hearts were assigned randomly to one of the following groups; 1) Control, no other intervention either before or after LCA occlusion; 2) EGCG1, 1 μM of EGCG; and 3) EGCG10, 10 μM of EGCG (Fig. 1). Following subgroup hearts were used to determine the involvement of KATP channels in EGCG induced cardioprotection using a nonselective KATP channel blocker GLI and a selective mKATP channel blocker HD; 4) EGCG + GLI EGCG with 10 μM GLI; 5) EGCG + HD; EGCG with 100 μM HD; 6) GLI alone; and 7) HD alone. Compounds were infused for 40 min, from 10 min before to the end of index ischemia. Drugs were diluted with Krebs-Henseleit solution to the required final concentrations, as described above, on the day of each experiment. The concentrations of KATP channel blockers used in this study were based on previous studies for isolated working rat hearts (13, 14).

Exclusion criteria

We decided prospectively that any hearts with a heart rate less than 250 beats/min, or coronary flow more than 18 mL/min or less than 8 mL/min at the end of stabilization would be excluded from the study. Hearts failing to develop LVSP of more than 80 mmHg when the LVEDP was kept 5-10

![Fig. 1. Experimental protocols. For measurement of contractile function and infarct size, isolated rat hearts were exposed to 30 min ischemia followed by 2 hr reperfusion. Drugs were perfused from 10 min before and to the end of index ischemia. EGCG, polyphenol (-)-epigallocatechin gallate.](image-url)
mmHg and hearts exhibiting arrhythmia during stabilization period also discarded.

**Determination of area at risk and infarct size**

At the end of each experiment (2 hr after reperfusion), the area at risk (AAR) and area at necrosis (AN) were measured as described in our previous study (11). In brief, LCA perfusion circuit was reoccluded, and diluted fluorescent polymer microspheres with 2-9 μm in diameter were infused to demarcate the AAR. The hearts were weighed, frozen at -20°C for 1-3 hr, and cut into 2 mm thick transverse slices using a rat heart slice matrix (Zivic Instruments, Pittsburgh, PA, USA). The slices were incubated in 1% TTC in sodium phosphate buffer (pH 7.4) at 37°C for 20 min. The slices were immersed in 10% formalin to enhance the contrast between viable (stained) and necrotic (unstained) tissue. LV was removed from the remaining tissue and then the LV slices were compressed to a uniform 2 mm thickness by placing them (basal side) between two glass plates separated by a 2 mm space. The AAR of myocardium was identified by illuminating the slices with U.V. light as the tissue without fluorescence. The AN (unstained by TTC) and AAR (no fluorescence) zone regions were traced on a clear acetate transparent sheet and quantified with the Image Tool (UTHSCSA Image Tool, version 3.0). The volume of AN was expressed as a percentage of the AAR volume. All measurements were performed in a blinded fashion.

**Statistical analysis**

Data are expressed as means ± SEM. Data analysis was performed with a personal computer statistical software package (SPSS for Windows, Release 12.0; SPSS Inc, Chicago, IL, USA). One-way analysis of variance with Tukey’s HSD post hoc test was used to determine whether any significant differences existed in cardiodynamic parameters and infarct measurements between groups. Chi square analysis was used to test differences in the incidence of VF. Differences were considered to be statistically significant when P values were less than 0.05.

**RESULTS**

A total of 53 rat hearts were used for this experiment. All hearts presented in results were perfused within 30-40 sec after excision. Three hearts were excluded from data analysis for the following reasons: coronary flow >18 mL/min (n=1), LVDP <80 mmHg (n=1), or heart rate <250 beats/min (n=1) during the stabilization period. Therefore, we report the data for 50 successfully completed infarct experiments.

**Incidence of ventricular fibrillation**

No heart had VF during ischemia or after 30 min of reperfusion. VF occurred during early reperfusion and appeared either as a transient self-limiting episode or as a persistent episode which need finger flick cardioversion. VF occurred in 17 of 50 hearts (3/8 in control, 2/7 in EGCG1, 2/7 in EGCG10, 2/7 in EGCG+GLI, 2/7 in GLI, 3/7 in EGCG+HD, and 3/7 in HD) during early reperfusion. There was no significant difference in the incidence of VF among groups.

**Determination of infarct size**

Table 1 presents body weight, heart weight, and LV volume. There were no significant differences in these parameters among the groups. Table 1 also presents risk volume data for the groups. Risk volume averaged 0.275 cm³ to 0.320 cm³ and was not statistically different among groups (P>0.05). The mean AAR for each experimental group ranged from 53.6% to 63.2% for LV volume. There were no significant differences in the ratio of AAR to LV volume among the groups (P>0.05). The changes in the infarct size observed between various groups and these results indicates that all groups were subjected to equivalent degrees of regional ischemia. This result means that the changes in the infarct size observed between various groups in our experiments were not related to the degree of ischemic area.

**Table 1. Morphometrics of the experimental rats**

| Groups      | No. | Body weight (g) | Heart weight (g) | LV volume (cm³) | AAR volume (cm³) | AAR/LV (%) |
|-------------|-----|-----------------|------------------|-----------------|------------------|------------|
| Control     | 8   | 303.1±6.2       | 1.43±0.05        | 0.500±0.022     | 0.289±0.014      | 58.2±2.9   |
| EGCG1       | 7   | 315.0±4.2       | 1.40±0.04        | 0.508±0.050     | 0.285±0.038      | 55.4±3.0   |
| EGCG10      | 7   | 317.9±3.4       | 1.41±0.05        | 0.494±0.029     | 0.294±0.023      | 59.7±3.9   |
| EGCG+GLI    | 7   | 309.3±5.6       | 1.44±0.03        | 0.485±0.018     | 0.287±0.018      | 60.1±4.9   |
| GLI         | 7   | 300.0±4.9       | 1.41±0.02        | 0.489±0.020     | 0.305±0.008      | 63.2±3.7   |
| EGCG+HD     | 7   | 314.3±3.2       | 1.36±0.05        | 0.516±0.029     | 0.320±0.015      | 62.4±2.3   |
| HD          | 7   | 307.1±6.4       | 1.35±0.05        | 0.512±0.038     | 0.275±0.026      | 53.6±2.9   |

Values are mean±SEM.

No., number of hearts; LV, left ventricle; AAR, area at risk; EGCG, polyphenol (-)-epigallocatechin gallate; EGCG1, 1 μM EGCG; EGCG10, 10 μM EGCG; GLI, 10 μM glibenclamide (a nonselective K⁺-ATP channel blocker); HD, 100 μM 5-hydroxydecanoate (a mitochondrial K⁺-ATP channel blocker).
As shown in Fig. 2, infarct volume in the control hearts was 27.2 ± 1.4% of the AAR zone. The ratio of infarct volume/ischemic volume (AN/AAR) in our control hearts was smaller than those reported by others (11, 12), however, this is in agreement with our recently reported study (13).

EGCG treatment during ischemic period significantly reduced myocardial infarction (14.5 ± 2.5% in 1 μM EGCG and 4.0 ± 1.7% in 10 μM EGCG, P<0.001 vs. control). The AN/AAR was more markedly attenuated by 10 μM EGCG than by 1 μM EGCG (P<0.003). To confirm the involvement of K\textsubscript{ATP} channels in infarct limitation effect by EGCG, we examined whether a nonselective K\textsubscript{ATP} channel blocker GLI and a selective mK\textsubscript{ATP} channel blocker HD could limit the anti-infarct effect by 1 μM EGCG. The infarct limitation effect by 1 μM of EGCG was totally abrogated by 10 μM GLI (24.6 ± 1.5%, P<0.001 vs. EGCG). Similarly, 100 μM HD also aborted the anti-infarct effect of EGCG (24.1 ± 1.2%, P<0.001 vs. EGCG) (Fig. 3). Treatment of control hearts with GLI or HD alone had infarct size of 23.7 ± 2.5% and 21.0 ± 1.0%, respectively, which were not different compared with the infarct size in the untreated control hearts (P>0.05).

Cardiac function recovery

The baseline coronary flow and cardiac function parameters are given in Table 2. There were no significant differences in coronary flow and hemodynamic indexes concerning heart rate, LVDP, RPP, +dP/dt\text{max}, and -dP/dt\text{min} at baseline among the groups. There were no significant differences in coronary flow and heart rate among groups throughout the experiments (data not shown). The LVDP, RPP, +dP/dt\text{max}, and -dP/dt\text{min} after 2 hr of reperfusion in control hearts were 48.0 ± 3.3%, 290.9 ± 13.7 (mmHg/sec/10\(^3\)), 303.6 ± 13.7 (beats/min), and 320.0 ± 13.7 (mmHg/min/10\(^3\)), respectively.

![Fig. 2](image-url) Fig. 2. Area at necrosis (AN) expressed as a percentage of the AAR (area at risk) in control hearts and hearts treated with the polyphenol (-)-epigallocatechin gallate (EGCG). Open circles indicate the infarct sizes from individual hearts. Filled circles in each group indicate the group mean infarct size; mean ± SEM. Both concentrations (1 and 10 μM) of EGCG during ischemic period significantly attenuate AN/AAR in isolated rat hearts. EGCG1, 1 μM EGCG; EGCG10, 10 μM EGCG.

![Fig. 3](image-url) Fig. 3. Area at necrosis (AN) expressed as a percentage of the AAR (area at risk) by treatment of 10 μM glibenclamide (GLI) and 100 μM 5-hydroxydecanoate (HD) combined with 1 μM polyphenol (-)-epigallocatechin gallate (EGCG) during ischemic period in isolated rat hearts. Open circles indicate the infarct sizes from individual hearts. Filled circles in each group indicate the group mean infarct size; mean ± SEM. Both a nonselective K\textsubscript{ATP} channel blocker GLI and a mitochondrial K\textsubscript{ATP} channel blocker HD totally blocked the anti-infarct effect by EGCG. Treatment of control hearts with GLI or HD alone had no effect on infarct size. *P<0.001 vs. control.

Table 2. Baseline coronary flow and cardiodynamic data

| Groups  | No. | CF (mL/min) | HR (beats/min) | LVDP (mmHg) | RPP (mmHg/min/10\(^3\)) | +dP/dt\text{max} (mmHg/sec/10\(^3\)) | -dP/dt\text{min} (mmHg/sec/10\(^3\)) |
|---------|-----|-------------|----------------|-------------|--------------------------|---------------------------------|---------------------------------|
| Control | 8   | 12.9 ± 0.2  | 281.0 ± 8.8    | 115.9 ± 11.3 | 34.0 ± 2.9               | 2.4 ± 0.1                       | 2.4 ± 0.1                       |
| EGCG1   | 7   | 13.4 ± 0.6  | 293.3 ± 5.4    | 117.5 ± 6.8  | 34.5 ± 2.1               | 2.5 ± 0.2                       | 2.4 ± 0.1                       |
| EGCG10  | 7   | 13.6 ± 0.6  | 290.9 ± 7.7    | 114.7 ± 10.3 | 32.3 ± 2.7               | 2.5 ± 0.2                       | 2.4 ± 0.2                       |
| EGCG+GLI| 7   | 13.1 ± 0.4  | 303.6 ± 4.5    | 123.5 ± 2.4  | 37.5 ± 1.0               | 2.6 ± 0.1                       | 2.4 ± 0.1                       |
| GLI     | 7   | 12.6 ± 0.7  | 291.6 ± 7.4    | 116.9 ± 4.7  | 34.0 ± 1.4               | 2.7 ± 0.2                       | 2.5 ± 0.2                       |
| EGCG+HD | 7   | 12.4 ± 0.4  | 282.2 ± 3.5    | 113.5 ± 5.8  | 32.1 ± 2.0               | 2.3 ± 0.2                       | 2.2 ± 0.2                       |
| HD      | 7   | 12.3 ± 0.4  | 295.3 ± 7.8    | 112.4 ± 10.1 | 32.3 ± 3.1               | 2.5 ± 0.2                       | 2.1 ± 0.1                       |

Values are mean ± SEM.

No., number of hearts; CF, coronary flow; HR, heart rate; LVDP, left ventricular developed pressure; RPP, rate-pressure product; +dP/dt\text{max}, maximum positive left ventricular pressure derivative; -dP/dt\text{min}, minimum negative left ventricular pressure derivative; EGCG, polyphenol (-)-epigallocatechin gallate; EGCG1, 1 μM EGCG; EGCG10, 10 μM EGCG; GLI, 10 μM glibenclamide (a nonselective K\textsubscript{ATP} channel blocker); HD, 100 μM 5-hydroxydecanoate (a mitochondrial K\textsubscript{ATP} channel blocker).
LVDP, RPP, +dP/dtmax, and -dP/dtmin after 2 hr of reperfusion. ischemia did not change the functional recovery concerning derivative of left ventricular pressure derivative. product; +dP/dtmax and -dP/dtmin, maximum and minimum of first derivative of left ventricular pressure derivative.

46.1 ± 3.6%, 49.1 ± 3.8%, and 46.7 ± 2.4%, respectively, of the baseline levels. The functional recovery parameters by EGCG after 2 hr of reperfusion were not different with control hearts (Fig. 4).

DISCUSSION

The treatment of EGCG, a major polyphenolic substance found in green tea, during ischemia significantly attenuated the infarct size after 2 hr of reperfusion in our isolated rat hearts. The current results confirm that EGCG treatment during ischemia protects against myocardial infarction. The infarct limitation effect by EGCG was totally abolished by a nons-selective KATP channel blocker GLI, indicating the involvement of mKATP (sarcKATP) channels via interacting with lipid membrane and receptor, thereby lessens its protective effects. It is suggested that oral ingestion more than 50 cups of green tea is required to achieve 10 μM EGCG concentration in the human plasma and oral intake of green tea for 3 cups in fasting state and 10 cups in feast state can achieve 1 μM EGCG concentration in human plasma. In this regard, it is considered that EGCG concentration more than 10 μM may not be suitable to clinical settings to evaluate the efficacy of EGCG in myocardial ischemic injury. In our preliminary study, application to the bath solution of natural green tea extract containing a 1 μM EGCG during ischemic period significantly attenuated infarct volume of the LV volume (10.3 ± 1.1%, n=8) compared with untreated myocardial I/R rat hearts (27.4 ± 2.1%, n=8, P<0.05). This is the reason that we used 1 μM EGCG for further experiment to investigate the involvement of KATP channels in the infarct limitation effect induced by EGCG, although the anti-infarct effect was more prominent in 10 μM EGCG preconditioned hearts.

It is well known that [Ca2+]i overload is closely correlated with myocardial damage and cell death during ischemia. In myocardium, sarcKATP channels were originally postulated to participate in salvage from irreversible I/R injury, because their opening would produce an increase in the outward potassium current leading to shortening of action potential duration, which would in turn reduce the Ca2+ influx through voltage-dependent Ca2+ channels and increase the time during which the Na+/Ca2+ exchanger would operate to extrude Ca2+ from the cell (18). We have reported previously that EGCG can modulate sarcKATP channels via reducing its sensitivity to ATP, which closes the channel, and to phosphatidylinositol polyphosphates (PIP), which open the channel (19). The potency of EGCG to reduce the channel ATP sensitivity is revealed to be greater in the cardiac-type channels than in the beta cell-type channels. Therefore, it can be speculated that reduced ATP sensitivity of cardiac KATP channels by EGCG may be, at least partially, related with EGCG-mediated cardioprotection. However, this hypothesis should be further determined because the channelPIP sensitivity can also be reduced by EGCG, resulting in the channel be difficult to open.

It is well accepted that ischemia causes increases in intramitochondrial calcium concentrations ([Ca2+]i), resulting in further calcium-dependent events leading to cell damage. As calcium enters the mitochondria during ischemia, water follows, leading to mitochondrial matrix swelling and eventually mitochondrial rupture and myocyte death. The opening of mKATP channels results in mitochondrial K+ influx, undergoing myocardial ischemia. Besides we expressed the infarct volume as a percentage of the AAR volume of the LV volume, but they measured the infarct size by measuring the infarct area against the whole heart including right ventricle. Otherwise, it may be attributable to the fact that high concentrations of EGCG (100 μM) directly inhibits sarcoplasmic reticulum (sarcKATP) channels via interacting with lipid membrane (14), thereby lessens its protective effects.
EGCG Reduces Myocardial Ischemic Injury

expansion of the mitochondrial matrix volume, and a reduction of the inner mitochondrial membrane potential established by the proton pump. This change is expected to decrease the driving force for Ca\(^{2+}\) influx, therefore attenuating [Ca\(^{2+}\)]\(_i\) overload under conditions (such as I/R) in which cytosolic calcium is increased (21). Therefore, opening of mK\(_{ATP}\) channels has been proposed to play an important role in cardiac protection such as in ischemic and pharmacological preconditioning (22). The current results, indicating that the EGCG-induced anti-infarct effect is totally inhibited by HD, suggest that mK\(_{ATP}\) channel opening by EGCG during ischemia may be directly responsible for cardioprotection. Tissue salvage by an anti-infarct intervention would lead to an improvement in cardiac function. The increase in [Ca\(^{2+}\)]\(_i\) is likely to explain the depressed ability of I/R hearts to generate contractile force (23, 24). However, reduction in infarct size is not always associated with an improvement in functional recovery due to the continued stunning or the possibility that the salvaged tissue is not yet normal (25). In a previous study, preischemic infusion of EGCG (100 \(\mu\)M) significantly ameliorated cardiac function during postischemic phase (5). However, no significant difference was observed in the treatment of 1 \(\mu\)M EGCG, which is more reliable concentration in clinical settings, during ischemia compared to control group in our isolated rat hearts, although there was significant infarct extent limitation effect. The interaction between mitochondrial permeability transition pores (mPTP) and the mK\(_{ATP}\) channels was previously suggested by findings indicating that diazoxide (an mK\(_{ATP}\) channel opener) -induced preconditioning was inhibited by an mPTP opener atractyloside (26, 27). A role for mPTP inhibition was also suggested in pharmacological preconditioning produced by volatile anesthetics desflurane (28, 29). Therefore, the possibility of the involvement of mPTP by EGCG treatment should be determined in the future.

In conclusion, perfusion of EGCG during ischemia significantly reduces infarct size after reperfusion and the mK\(_{ATP}\) channels play a crucial role in EGCG induced cardioprotection.

REFERENCES

1. Sano J, Inami S, Seimiyi K, Obha T, Sakai S, Takano T, Mizuno K. Effects of green tea intake on the development of coronary artery disease. Circ J 2004; 68: 665-70.
2. Hidgon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Curr Rev Food Sci Nutr 2003; 43: 89-143.
3. Kuriyama S, Shimazu T, Ohtani K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296: 1255-65.
4. Aneja R, Hake PW, Burroughs TJ, Denenberg AG, Wong HR, Zingarelli B. Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med 2004; 10: 55-62.
5. Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M, Suzuki H, Knight RA, Latchman DS, Stephanou A. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J 2004; 18: 1621-3.
6. Tani M. Mechanisms of Ca\(^{2+}\) overload in reperfused ischemic myocardium. Annu Rev Physiol 1990; 52: 543-59.
7. Ylitalo KV, Ala-Rami A, Simellova EV, Peukkurinen KJ, Hassinen IE. Intracellular free calcium and mitochondrial membrane potential in ischemia/reperfusion and preconditioning. J Mol Cell Cardiol 2000; 32: 1223-38.
8. Garlid KD, Pasurek P, Yarov-Yarovoy V, Murray RN, Darbenzio RB, D’Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 1997; 81: 1072-82.
9. O’Rourke B. Myocardial K (ATP) channels in preconditioning. Circ Res 2000; 87: 845-55.
10. Grover GJ, D’Alonzo AJ, Garlid KD, Baigur R, Lodge NJ, Sleph PG, Darbenzio RB, Hess TA, Smith MA, Pasurek P, Atwal KS. Pharmacologic characterization of BMS-191095, a mitochondrial K\(_{ATP}\) opener with no peripheral vasodilator or cardiac action potential shortening activity. J Pharmacol Exp Ther 2001; 297: 1184-92.
11. Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M. PK\(_{II}\)-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res 2006; 69: 178-85.
12. Burley DS, Baxter GF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 2007; 102: 529-41.
13. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008; 108: 243-50.
14. Back WK, Jung BC, Lim JH, Kwon TK, Lee HY, Cho CH, Kim DK, Shin DH, Park JG, Lim JG, Bae JH, Yoo SK, Park WK, Song DK. Inhibitory modulation of ATP-sensitive potassium channels by gallate-ester moiety of (-)-epigallocatechin-3-gallate. Biochem Pharmacol 2005; 70: 1560-7.
15. Shinozaka T, Takashashi N, Kohno H, Yamanaka K, Ooie T, Wakisaka O, Murozono Y, Taniguchi Y, Torigoe Y, Hara M, Shimada T, Saikawa T, Yoshimatsu H. Mitochondria are targets for geranylgeranylatedcetone-induced cardioprotection against ischemia-reperfusion in the rat heart. Am J Physiol Heart Circ Physiol 2007; 293: H1892-9.
16. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Hara Y, Alberts DS. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005; 11: 4627-33.
17. Liu H, Wang L, Eaton M, Schafer S. Sevofurane preconditioning limits intracellular/mitochondrial Ca\(^{2+}\) in ischemic newborn myocardium. Anesth Analg 2005; 101: 349-55.
18. Tani M, Neely JR. Role of intracellular Na+ and Ca\(^{2+}\) overload and...
depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of \( H^+/-Na^+ \) and \( Na^+/-Ca^{2+} \) exchange. Circ Res 1989; 65: 1045-56.

19. Jin JY, Park SH, Bae JH, Cho HC, Lim JG, Park WS, Han J, Lee JH, Song DK. Uncoupling by (-)-epigallocatechin-3-gallate of ATP-sensitive potassium channels from phosphatidylinositol polyphosphates and ATP. Pharmacol Res 2007; 56: 237-47.

20. Wang L, Cherednichenko G, Hernandez L, Halow J, Camacho SA, Figueredo V, Schaefer S. Preconditioning limits mitochondrial \( Ca^{2+} \) during ischemia in rat hearts: role of \( K_{ATP} \) channels. Am J Physiol Heart Circ Physiol 2001; 280: H2321-8.

21. Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol 1996; 28 (Suppl 1): S1-10.

22. Holmuhamedov EL, Jovanović S, Dreja PP, Jovanović A, Terzic A. Mitochondrial ATP-sensitive \( K^+ \) channels modulate cardiac mitochondrial function. Am J Physiol 1998; 275: H1567-76.

23. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol 1993; 88: 456-70.

24. Meissner A, Morgan JP. Contractile dysfunction and abnormal \( Ca^{2+} \) modulation during posts ischemic reperfusion in rat heart. Am J Physiol 1995; 268: H100-11.

25. Lochner A, Genen S, Moolman JA. Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Basic Res Cardiol 2003; 98: 337-46.

26. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-43.

27. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003; 93: 292-301.

28. Krolikowski JG, Bienengraeber M, Weihrauch D, Wartier DC, Kersten JR, Pagel PS. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial \( K_{ATP} \) channels. Anesth Analg 2005; 101: 1590-6.

29. Piriou V, Chiari P, Gateau-Roesch O, Argaud L, Muntean D, Salles D, Loufouat J, Gueugniaud PY, Lehot JJ, Ovize M. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 2004; 100: 581-8.